Healthcare Business Rewind: No Charges For DaVita, Vivus’s Huge Support

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

The United States Justice Department will not file charges against Dialysis clinic operator DaVita (NYSE:DVA) while it dropped a seven-year civil and criminal inquiry into the firm’s financial and marketing practices.

Vivus (NASDAQ:VVUS) has enjoyed higher than anticipated support for its new Qsymia drug on its first week on the market. Weight loss therapies are highly needed or desirable, but it is the okay of health experts and insurer coverage that make or break a brand.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Shares of Acorda Therapeutics (NASDAQ:ACOR) moved up on heavy volume on the day, following S&P’s announcement late Monday that the stock would be added to the S&P SmallCap 600 index.

Cigna Corporation (NYSE:CI) drew the remark that the firm is a “boring homework exercise with potential for big rewards” from David Einhorn, adding that fear and uncertainly concerning Obamacare has left HMOs inexpensive, and that “Even when HMOs make less than expected, they make a lot.”

Don’t Miss: AstraZeneca’s New Strategy.


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business